Correspondence to ‘Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data’

We read with great interest the article by Singh and Cleveland, which the authors reported that the observed hypersensitivity reactions (HSRs) associated with allopurinol and febuxostat were not different.1 This conclusion differs from previous studies on HSRs associated with allopurinol and febuxos...

Full description

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 81; no. 6; p. e107
Main Authors Ma, Kevin Sheng-Kai, Wei, James Cheng-Chung, Chung, Wen-Hung
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group Ltd and European League Against Rheumatism 01.06.2022
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:We read with great interest the article by Singh and Cleveland, which the authors reported that the observed hypersensitivity reactions (HSRs) associated with allopurinol and febuxostat were not different.1 This conclusion differs from previous studies on HSRs associated with allopurinol and febuxostat using claimed data2 and intramural databases.3 The discrepancy may arise from different inclusion criteria for the diagnosis of HSRs based on International Classification of Diseases, Ninth Revision (ICD-9) coding system, methods for identifying causative drugs, methods for stratification, as well as ethnicity of the involved population.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-2
content type line 14
ObjectType-Letter to the Editor-1
ObjectType-Correspondence-1
ObjectType-Commentary-2
content type line 23
ISSN:0003-4967
1468-2060
1468-2060
DOI:10.1136/annrheumdis-2020-218090